Determinants of retinoid X receptor transcriptional antagonism

Journal of Medicinal Chemistry

Volumn 47, Issue 18, 2004, Pages 4360-4372

  Cavasotto, Claudio N ^b   Liu, Gang ^a   James, Sharon Y ^a   Hobbs, Peter D ^c   Peterson, Valerie J ^d   Bhattacharya, Ananyo A ^a   Kolluri, Siva K ^a   Zhang, Xiao Kun ^a   Leid, Mark ^d   Abagyan, Ruben ^e   Liddington, Robert C ^a   Dawson, Marcia I ^a  

^a BURNHAM INSTITUTE   (United States)

^b Molsoft LLC   (United States)

^c SRI INTERNATIONAL   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3' N BUTYL 5',6',7',8' TETRAHYDRO 5',5',8',8' TETRAMETHYL 2' NAPHTHALENYL)(CYCLOPROPYLIDENE)METHYL]BENZOIC ACID; ALITRETINOIN; ARGININE; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR SUBTYPE; RETINOIC ACID RECEPTOR BETA; RETINOID; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DESIGN; DRUG DETERMINATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LIGAND BINDING; RECEPTOR BLOCKING; TRANSCRIPTION REGULATION;

BENZOIC ACIDS; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; ELECTROSTATICS; HUMANS; LIGANDS; PLIABILITY; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 4143083687     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030651g     Document Type: Article

References (54)

1. Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. The retinoid receptors. In The Retinoids: Biology, Chemistry, and Medicine; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994; pp 319-349.
2. Bourguet, W.; Vivat, V.; Wurtz, J. M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 2000, 5, 289-298.
3. Renaud, J. P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RARγ ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378, 681-689.
4. Botling, J.; Castro, D. S.; Oberg, F.; Nilsson, K.; Perlmann, T. Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation. J. Biol. Chem. 1997, 272, 9443-9449.
5. Gampe, R. T., Jr.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5, 545-555.
6. Germain, P.; Iyer, J.; Zechel, C.; Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 2002, 415, 187-192.
7. Egea, P. F.; Mitschler, A.; Moras, D. Molecular recognition of agonist ligands by RXRs. Mol. Endocrinol. 2002, 16, 987-997.
8. Lehmann, J. M.; Jong, L.; Fanjul, A.; Cameron, J. F.; Liu, X. P.; Haefner, P.; Dawson, M. I.; Pfahl, M. A novel class of retinoids, selective for retinoid X receptor response pathways. Science 1992, 258, 1944-1946.
9. Dawson, M. I.; Zhang, X.; Hobbs, P. D.; Jong, L. Synthetic retinoids and their usefulness in biology and medicine. In Vitamin A and Retinoids: An Update of Biological Aspects and Clinical Applications; Livrea, M. A., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2000; pp 161-196.
10. Gronemeyer, H.; Miturski, R. Molecular mechanisms of retinoid action. Cell. Mol. Biol. Lett. 2001, 6, 3-52.
11. Dawson, M. I.; Zhang, X.-K. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr. Med. Chem. 2002, 9, 623-637.
12. Kagechika, H. Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr. Med. Chem. 2002, 9, 591-608.
13. Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W. R.; Pfahl, M.; Lee, M.-O.; Shroot, B. Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. J. Med. Chem. 1995, 38, 3368-3383.
14. 2-bridged diaryl retinoids: Effects of bridge-region substitution on retinoid X receptor (RXR) selectivity. Bioorg. Med. Chem. Lett. 2000, 10, 1307-1310.
15. Umemiya, H.; Fukasawa, H.; Ebisawa, M.; Eyrolles, L.; Kawachi, E.; Eisenmann, G.; Gronemeyer, H.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J. Med. Chem. 1997, 40, 4222-4234.
16. Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 1994, 37, 2930-2941.
17. Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, J. A.; Heyman, R. A.; Nadzan, A. M. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 1995, 38, 3146-3155.
18. Canan Koch, S. S.; Dardashti, L. J.; Cesario, R. M.; Croston, G. E.; Boehm, M. F.; Heyman, R. A.; Nadzan, A. M. Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells. J. Med. Chem. 1999, 42, 742-750.
19. Ebisawa, M.; Umemiya, H.; Ohta, K.; Fukasawa, H.; Kawachi, E.; Christoffel, G.; Gronemeyer, H.; Tsuji, M.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem. Pharm. Bull. 1999, 47, 1778-1786.
20. Takahashi, B.; Ohta, K.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Kagechika, H. Novel retinoid X receptor antagonists: Specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J. Med. Chem. 2002, 45, 3327-3330.
21. Yamauchi, T.; Waki, H.; Kamon, J.; Murakami, K.; Motojima, K.; Komeda, K.; Miki, H.; Kubota, N.; Terauchi, Y.; Tsuchida, A.; Tsuboyama-Kasaoka, N.; Yamauchi, N.; Ide, T.; Hori, W.; Kato, S.; Fukayama, M.; Akanuma, Y.; Ezaki, O.; Itai, A.; Nagai, R.; Kimura, S.; Tobe, K.; Kagechika, H.; Shudo, K.; Kadowaki, T. Inhibition of RXR and PPARy ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest. 2001, 108, 1001-1013.
22. Canan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Identification of the first retinoid X receptor homodimer antagonist. J. Med. Chem. 1996, 39, 3229-3234.
23. Cavasotto, C. N.; Orry, A. J.; Abagyan, R. A. Structure-based identification of binding sites, native ligands and potential inhibitors for G-protein coupled receptors. Proteins 2003, 51, 423-433.
24. Cavasotto, C. N.; Abagyan, R. A. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 2004, 337, 209-225.
25. Vivat, V.; Zechel, C.; Wurtz, J. M.; Bourguet, W.; Kagechika, H.; Umemiya, H.; Shudo, K.; Moras, D.; Gronemeyer, H.; Chambon, P. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J. 1997, 16, 5697-5709.
26. Apfel, C.; Bauer, F.; Crettaz, M.; Forni, L.; Kamber, M.; Kaufmann, F.; LeMotte, P.; Pirson, W.; Klaus, M. A retinoic acid receptor α antagonist selectively counteracts retinoic acid effects. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7129-7133.
27. Lee, M.-O.; Hobbs, P. D.; Zhang, X.-K.; Dawson, M. I.; Pfahl, M. A synthetic retinoid antagonist inhibits the human immunodeficiency virus type 1 promoter. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 5632-5636.
28. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
29. Xu, X. C.; Sozzi, G.; Lee, J. S.; Lee, J. J.; Pastorino, U.; Pilotti, S.; Kurie, J. M.; Hong, W. K.; Lotan, R. Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: Implications for lung cancer development. J. Natl. Cancer Inst. 1997, 89, 624-629.
30. Xu, X. C.; Sneige, N.; Liu, X.; Nandagiri, R.; Lee, J. J.; Lukmanji, F.; Hortobagyi, G.; Lippman, S. M.; Dhingra, K.; Lotan, R. Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis. Cancer Res. 1997, 57, 4992-4996.
31. Li, X.-S.; Shao, Z.-M.; Sheikh, M. S.; Eiseman, J. L.; Sentz, D.; Jetten, A. M.; Chen, J.-C.; Dawson, M. I.; Aisner, S.; Rishi, A. K.; Fontana, J. A. Retinoic acid nuclear receptor β (RARβ) inhibits breast carcinoma anchorage independent growth. J. Cell. Physiol. 1995, 165, 449-458.
32. Liu, Y.; Lee, M.-O.; Wang, H.-G.; Li, Y.; Hashimoto, Y.; Klaus, M.; Reed, J. C.; Zhang, X. RARβ mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 1996, 16, 1138-1149.
33. James, S. Y.; Lin, F.; Kolluri, S. K.; Dawson, M. I.; Zhang, X.-K. Regulation of retinoic acid receptor β expression by peroxisome proliferator-activated receptor y ligands in cancer cells. Cancer Res. 2003, 63, 3531-3538.
34. Peterson, V. J.; Barofsky, E.; Deinzer, M. L.; Dawson, M. I.; Feng, K.-C.; Zhang, X.-K.; Madduru, M. R.; Leid, M. Mass-spectrometric analysis of agonist-induced retinoic acid receptor y conformational change. Biochem. J. 2002, 362, 173-181.
35. Egea, P. F.; Mitschler, A.; Rochel, N.; Ruff, M.; Chambon, P.; Moras, D. Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid. EMBO J. 2000, 19, 2592-2601.
36. ICM Manual, 3rd ed.; Molsoft L.L.C.: La Jolla, CA, 2003.
37. Love, J. D.; Gooch, J. T.; Benko, S.; Li, C.; Nagy, L.; Chatterjee, V. K.; Evans, R. M.; Schwabe, J. W. The structural basis for the specificity of retinoid-X receptor-selective agonists: New insights into the role of helix H12. J. Biol. Chem. 2002, 277, 11385-11391.
38. Sakashita, A.; Kizaki, M.; Pakkala, S.; Schiller, G.; Tsuruoka, N.; Tomosaki, R.; Cameron, J. F.; Dawson, M. I.; Koeffler, H. P. 9-cis-Retinoic acid: Effects on normal and leukemic hematopoiesis in vitro. Blood 1993, 81, 1009-1016.
39. Dawson, M. I.; Chan, R. L.-S.; Derdzinski, K.; Hobbs, P. D.; Chao, W.-R.; Schiff, L. J. Synthesis and pharmacological activity of 6-[(E)-2-(2,6,6- trimethyl-1-cyclohexen-1-yl)ethen-1-yl]-and 6-(1,2,3,4-tetrahydro-1,1,4,4- tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acids. J. Med. Chem. 1983, 26, 1653-1656.
40. Faul, M. M.; Ratz, A. M.; Sullivan, K. A.; Trankle, W. G.; Winneroski, L. L. Synthesis of novel retinoid X receptor-selective retinoids. J. Org. Chem. 2001, 66, 5772-5782.
41. Abagyan, R.; Totrov, M. Biased probability Monte-Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 1994, 235, 983-1002.
42. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM-A new method for protein modeling and design-Applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 1994, 15, 488-506.
43. Némethy, G.; Gibson, K. D.; Palmer, K. A.; Yoon, C. N.; Paterlini, G.; Zagari, A.; Rumsey, S.; Scheraga, H. A. Energy parameters in polypeptides. 10. Improved geometrical parameters and nonbonded interactions for use in the ECEPP/3 algorithm, with application to proline-containing peptides. J. Phys. Chem. 1992, 96, 6472-6484.
44. Abagyan, R. A.; Totrov, M. Ab initio folding of peptides by the optimal-bias Monte Carlo minimization procedure. J. Comput. Phys. 1999, 151, 402-421.
45. Metropolis, N.; Rosenbluth, A. W.; Rosenbluth, M. N.; Teller, A. H.; Teller, E. Equation of state calculations by fast computing machines. J. Chem. Phys. 1953, 21, 1087-1092.
46. Totrov, M.; Abagyan, R. The contour-buildup algorithm to calculate the analytical molecular surface. J. Struct. Biol. 1996, 116, 138-143.
47. Totrov, M.; Abagyan, R. Protein-ligand docking as an energy optimization problem. In Drug-Receptor Thermodynamics: Introduction and Experimental Applications; Raffa, R. B., Ed.; John Wiley and Sons: New York, 2001; pp 603-624.
48. Totrov, M.; Abagyan, R. Derivation of the sensitive discrimination potential for virtual ligand screening. In RECOMB '99: Proceedings of the Third Annual International Conference on Computational Molecular Biology; Waterman, M., Ed.; Associaton for Computer Machinery, New York: Lyon, France, 1999; pp 37-38.
49. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997, Suppl. 1, 215-220.
50. Schapira, M.; Totrov, M.; Abagyan, R. Prediction of the binding energy for small molecules, peptides and proteins. J. Mol. Recognit. 1999, 12, 177-190.
51. Leid, M. Ligand-induced alteration of the protease sensitivity of retinoid X receptor α. J. Biol. Chem. 1994, 269, 14175-14181.
52. Allegretto, E. A. Detection of RARs and RXRs in cells and tissues using specific ligand-binding assays and ligand-binding immunoprecipitation techniques. In Methods in Molecular Biology: Retinoid Protocols; Redfern, C. P. F., Ed.; Humana Press: Totowa, NJ, 1998; pp 219-232.
53. Zhang, X.-K.; Hoffmann, B.; Tran, P. B.; Graupner, G.; Pfahl, M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 1992, 355, 441-446.
54. Wu, Q.; Dawson, M. I.; Zheng, Y.; Hobbs, P. D.; Agadir, A.; Jong, L.; Li, Y.; Liu, R.; Lin, B.; Zhang, X.-K. Inhibition of transretinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol. Cell. Biol. 1997, 17, 6598-6608.